Goldman Sachs’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.8M | Sell |
30,800
-11,900
| -28% | -$5.55M | ﹤0.01% | 2786 |
|
|
2025
Q4 | $19.4M | Sell |
42,700
-14,000
| -25% | -$6.03M | ﹤0.01% | 2408 |
|
|
2025
Q3 | $22.2M | Buy |
56,700
+25,500
| +82% | +$10.7M | ﹤0.01% | 2154 |
|
|
2025
Q2 | $13.9M | Hold |
31,200
| – | – | ﹤0.01% | 2459 |
|
|
2025
Q1 | $15.1M | Sell |
31,200
-300
| -1% | -$140K | ﹤0.01% | 2297 |
|
|
2024
Q4 | $12.7M | Sell |
31,500
-3,000
| -9% | -$1.39M | ﹤0.01% | 2570 |
|
|
2024
Q3 | $16M | Sell |
34,500
-100
| -0.3% | -$48K | ﹤0.01% | 2259 |
|
|
2024
Q2 | $16.2M | Sell |
34,600
-9,600
| -22% | -$4.17M | ﹤0.01% | 2046 |
|
|
2024
Q1 | $18.5M | Buy |
44,200
+12,700
| +40% | +$5.37M | ﹤0.01% | 1907 |
|
|
2023
Q4 | $12.8M | Sell |
31,500
-2,400
| -7% | -$887K | ﹤0.01% | 2300 |
|
|
2023
Q3 | $11.8M | Sell |
33,900
-19,300
| -36% | -$6.75M | ﹤0.01% | 2259 |
|
|
2023
Q2 | $18.7M | Sell |
53,200
-60,900
| -53% | -$20.5M | ﹤0.01% | 1910 |
|
|
2023
Q1 | $35.9M | Buy |
114,100
+14,900
| +15% | +$4.47M | 0.01% | 1308 |
|
|
2022
Q4 | $28.6M | Buy |
99,200
+55,200
| +125% | +$16.8M | 0.01% | 1635 |
|
|
2022
Q3 | $12.7M | Buy |
+44,000
| New | +$12.7M | ﹤0.01% | 2283 |
|
|
2022
Q1 | – | Sell |
-20,900
| Closed | -$4.59M | – | 6929 |
|
|
2021
Q4 | $4.59M | Sell |
20,900
-4,200
| -17% | -$817K | ﹤0.01% | 3502 |
|
|
2021
Q3 | $4.55M | Sell |
25,100
-133,800
| -84% | -$26.1M | ﹤0.01% | 3444 |
|
|
2021
Q2 | $32M | Buy |
158,900
+85,000
| +115% | +$17.8M | 0.01% | 1648 |
|
|
2021
Q1 | $15.9M | Buy |
73,900
+63,800
| +632% | +$14M | ﹤0.01% | 2137 |
|
|
2020
Q4 | $2.39M | Sell |
10,100
-9,900
| -50% | -$2.27M | ﹤0.01% | 3601 |
|
|
2020
Q3 | $5.44M | Buy |
+20,000
| New | +$5.52M | ﹤0.01% | 2826 |
|
|
2020
Q2 | – | Sell |
-30,500
| Closed | -$7.26M | – | 5506 |
|
|
2020
Q1 | $7.26M | Buy |
30,500
+21,500
| +239% | +$4.93M | ﹤0.01% | 2338 |
|
|
2019
Q4 | $1.97M | Sell |
9,000
-10,700
| -54% | -$2.17M | ﹤0.01% | 3660 |
|
|
2019
Q3 | $3.34M | Buy |
+19,700
| New | +$3.49M | ﹤0.01% | 3154 |
|
|
2019
Q1 | – | Sell |
-91,300
| Closed | -$15.1M | – | 5472 |
|
|
2018
Q4 | $15.1M | Buy |
91,300
+40,000
| +78% | +$6.93M | ﹤0.01% | 2030 |
|
|
2018
Q3 | $9.89M | Sell |
51,300
-115,400
| -69% | -$20.5M | ﹤0.01% | 2467 |
|
|
2018
Q2 | $28.3M | Buy |
166,700
+76,200
| +84% | +$11.8M | 0.01% | 1632 |
|
|
2018
Q1 | $14.8M | Buy |
90,500
+43,600
| +93% | +$7.12M | ﹤0.01% | 2064 |
|
|
2017
Q4 | $7.03M | Sell |
46,900
-127,200
| -73% | -$18.8M | ﹤0.01% | 2722 |
|
|
2017
Q3 | $26.5M | Buy |
174,100
+140,700
| +421% | +$21.2M | 0.01% | 1771 |
|
|
2017
Q2 | $4.3M | Sell |
33,400
-14,500
| -30% | -$1.75M | ﹤0.01% | 3184 |
|
|
2017
Q1 | $5.24M | Sell |
47,900
-37,000
| -44% | -$3.26M | ﹤0.01% | 2904 |
|
|
2016
Q4 | $6.25M | Buy |
84,900
+50,800
| +149% | +$4.13M | ﹤0.01% | 2857 |
|
|
2016
Q3 | $2.97M | Sell |
34,100
-4,400
| -11% | -$416K | ﹤0.01% | 3487 |
|
|
2016
Q2 | $3.31M | Sell |
38,500
-8,300
| -18% | -$717K | ﹤0.01% | 3192 |
|
|
2016
Q1 | $3.72M | Sell |
46,800
-2,700
| -5% | -$244K | ﹤0.01% | 2944 |
|
|
2015
Q4 | $6.23M | Sell |
49,500
-24,000
| -33% | -$2.9M | ﹤0.01% | 2637 |
|
|
2015
Q3 | $7.65M | Buy |
73,500
+20,400
| +38% | +$2.62M | ﹤0.01% | 2485 |
|
|
2015
Q2 | $6.56M | Buy |
53,100
+22,600
| +74% | +$2.85M | ﹤0.01% | 2702 |
|
|
2015
Q1 | $3.6M | Sell |
30,500
-110,600
| -78% | -$13.3M | ﹤0.01% | 3214 |
|
|
2014
Q4 | $16.8M | Buy |
141,100
+14,600
| +12% | +$1.64M | 0.01% | 1941 |
|
|
2014
Q3 | $14.2M | Sell |
126,500
-343,500
| -73% | -$32.7M | ﹤0.01% | 2076 |
|
|
2014
Q2 | $44.5M | Buy |
470,000
+4,800
| +1% | +$337K | 0.01% | 1193 |
|
|
2014
Q1 | $32.9M | Buy |
465,200
+376,000
| +422% | +$29.8M | 0.01% | 1362 |
|
|
2013
Q4 | $6.63M | Buy |
89,200
+43,500
| +95% | +$3.03M | ﹤0.01% | 2767 |
|
|
2013
Q3 | $3.46M | Sell |
45,700
-191,600
| -81% | -$15.2M | ﹤0.01% | 3347 |
|
|
2013
Q2 | $19M | Buy |
+237,300
| New | +$17.5M | 0.01% | 1584 |
|
Other funds holding VRTX
VCM
VPM
Goldman Sachs's VRTX Position: Q1 2026 in Review
Goldman Sachs increased its Vertex Pharmaceuticals (VRTX) stake by 38% in Q1 2026, buying an estimated $310M and bringing the position to 2,417,875 shares worth $1.08B. The position accounts for 0.12% of the portfolio, ranked #152.
Goldman Sachs first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Goldman Sachs held 2,417,875 shares of Vertex Pharmaceuticals worth $1.08B as of Q1 2026.
- Goldman Sachs bought 663,757 Vertex Pharmaceuticals shares in Q1 2026, an estimated $310M.
- Vertex Pharmaceuticals made up 0.12% of Goldman Sachs's portfolio in Q1 2026, its #152 holding.
- Goldman Sachs first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.